Medicare Coverage Advisers Split On Renal Artery Stenting
This article was originally published in The Gray Sheet
Executive Summary
CMS' Medicare Evidence Development Coverage Advisory Committee (MedCAC) could not reach consensus on whether Medicare coverage of angioplasty and stenting to treat renal artery disease should be limited to patients in clinical trials
You may also be interested in...
No Added Benefit From Renal-Artery Stenting, Long-Delayed Study Concludes
The 947-patient CORAL trial shows renal-artery stenting does not prevent more adverse events than comprehensive medical therapy alone in people with atherosclerotic renal-artery stenosis and hypertension or chronic kidney disease.
CMS Gets Pushback For Playing Doctor In Renal Stenting Coverage Proposal
Stent manufacturers are urging CMS to finalize its draft coverage decision for renal stenting, though one aspect of the proposal has some wondering whether the agency is going too far in controlling physicians' interactions with patients
CMS Gets Pushback For Playing Doctor In Renal Stenting Coverage Proposal
Stent manufacturers are urging CMS to finalize its draft coverage decision for renal stenting, though one aspect of the proposal has some wondering whether the agency is going too far in controlling physicians' interactions with patients